Document 2519997

39
615.831:616-006-092.9
V.I. Ivanova-Radkevich, L.V. Umnova, S.V. Barkanova, E.A. Makarova, E.A. Lukyanets
PHOTODYNAMIC ACTIVITY
OF TETRAAZACHLORIN DERIVATIVE
Federal State Unitary Enterprise "GNC "NIOPIC", Moscow
ABSTRACT
High photodynamic activity of aqueous micellar solutions of N-methyl-pyrrolidine[3,4-b]tetraphenyl-tetraazachlorin
in 4% Cremophor EL (˜max 715 nm) has been demonstrated in in vivo studies on mice bearing Ehrlich tumor.
Key words: photodynamic therapy, photosensitizer, Ehrlich tumor, tetraazachlorin.
.. -<=, '.. , *.. "
, .. $, .. ';>
AB>
3 E
#B #?
@+ “! “+(”, $
%&$
' '%D= ("*= ' N-"[3,4-b](B ' '" ' 4% ( EL (˜ 715 ) ' \ in vivo %& "! #F .
/ %": ("*= =, (+B, # , B.
B
" ("*! (P) '
''" ' B E –
(+B, +"FQ +F B+# F ' #'! "#FQ +#* # * B#* [3–6]. @" 'B"!' ' "=
(* E, '"=Q +B'F
' #'! / #" # E* ' (' *, "), B#&FQ ##% \% #'!
[2; 7–9]. & " P "=
*= B*'% '+B'! #' '% (+B' ##*&% '!'. ="# '%D! ("*! \(('F 'D% '!' +B ='== '%! \((E Q= ' " "B, *
'=B #+! ("* 'B"!'=
'+B'. + '% "= P
(+B% # Q= '
+D ( "B (700–800 ), "
+' Q +*! , * +*' 'BD + #+ 3/ 7/2008
'= B#*= ' "' '%#F \((' [2; 3; 10].
F +% ='= "' (+B#FQ '!' "'= ' ("+% "! – B', , N-"[3,4-b](B (H2PyrTACPh4).
>
O >
BO
+T "'= ='= ' " B' – E%! (+B H2PyrTACPh4 [1].
"#%! B ='== (% " '"' \ ' '
'". @\# "= '"= \' in vivo
+% '% \# H2PyrTACPh4 ' '"
' 4% ( EL ( '-' 'Q') "D "!'#FQ 'Q' 0,05; 0,1; 0,3 0,6 /.
C+'#F '#'#F ("*#F ' +BE' H2PyrTACPh4 B#* %&- C) ! 18–22 B'"
«F'». @ + D'% #'"'' «@' "= '"= + CCUCU ?@?)L?CU H>
40
B' \% D'%» «D"#"% "E= (\* ") '"F "-+* "'! B' D'%».
! #'! "F #D "= ( E! E% . =
'' "! # B'"#F E#F
D", "DQ#F a2,2u106 #'% ,
'B=#F %&-" 7-! " #,
' "D #D#F '
+" D! '! *.
'% "# ''" D'% 7-! " # " #! ' ''#F '# ' "B 0,5; 1,0; 3,0 6,0 /
' %&.
# +#* '*
* "= P -1 %'%
B#*= (@ «@F»). ) \%
' H2PyrTACPh4 ' 4%- '"
( EL # Q= #=
" '% a715 (. 1), \# +"#F "= P "# '% B#*= (' +E! '(' C-18 -
$, ..
0,8
0,6
0,4
0,2
' %! # '= 12, ' ! – 15.
@"D +F"= B D'% '= 25 "! *=. '"=
P * #'% " ("* 'B"!'=.
@'#'%! \(( E' " B= +T # B*= D= # (). * B*%
* t50 %.
+T # (3) *%' (#:
V#=™/6u(D1uD2uD3),
" D1, D2 D3 – 3 'B "#=%
" #, .
(%) *%' (#:
={(V# ()–V# (%))/V# ())}u100%,
" V# (%) – "! +T # (3) '
%! # ' %! +F"=;
V# () – "! +T # (3) ' ! # D +F"=.
C*#F ++# B#' "'= '" B' Statistica
6,0 (StatSoft, CG). A "#F '%+# =" B#', #*% B +T' #! ' % " +T ' # D'%, "''&= "'# 'B"!'F.
= D"! '%+ *%' "#'
B* B* " =. '= "% '%+ EF E \((' B*% D'
'B"!'= # +% '%+ ! (=0,05).
#EO B
0,0
400
500
600
700
800
900
&
, %. 1. D!" %)! )"&".' %" 0,1 $&/$ H2PyrTACPh4 4%-"$ ""$
$"5" EL, l = 0,2 %$, | 715$ = 2,3u104
''! E! #= 700 CAC-26 "=
(E "''! * B#*=
'=, +B#= +B B#*= # a710 &! #'% a90
. @ Q +#*= ' QF B= Q @
(@ «@F»).
C+B'#F # +#* "E *B 0,5 24 * ''"= (+B ' "#% "B. @ Q +#*= '= a220 )/2, ''= "B
– a120 D/2. ) *' = B'
%&!-#!, "''&= #-+ 'B"!'F. C" *' D'%
3/ 7/2008
@'"% \% B, * ' #' +#*= ''" D'%#= H2PyrTACPh4 ' ! B
"'% "B (6,0 /) "'= \! # +F". +#*
+B'% #! ' B#
"= '"= P D D '" DF . A*= "= #B%
# '= ’10 % ' =D +F"=.
@ B#* ("*! '
+BE' H2PyrTACPh4 ' "B 0,5; 1,0; 3,0 6,0
/ '" +#*= *B 24 *
''"= +* B*
"' # =D '
+F"= * "= ' "B (+B, "B% 0,5 / (. 2). @
''" D'% H2PyrTACPh4 ' "B 6,0 /
B*= " 73–85 %; B' "B% 3,0 / – 55–72 %, D "B%
" 1,0 / – 54–59 %.
' & " B*= +T'
#! ' %% # ''" "# (+B ' "B 1,0; 3,0 6,0 /
'F "'D"% B# B QF = -.
CCUCU ?@?)L?CU H>
'" B # 3, Q ' ' D"# ''" (+B '" P 24 * " 0,5 * * '%D%! +*! \((, +F"%! =D 25 "! *= (B*= ' 54–67 %). B' = "'", * " B*= +T'
#! ' %% # B "'
&, * ' !.
1200
V % 41
1000
800
600
400
200
0
0
5
10
15
20
25
& '*
%. 2. %! ! 0$' "2C$
")*+" )"% AB ) %)",0"
H2PyrTACPh4 "0+ " 0,5 " 6,0 $&/!& 0 24 "
"2*'
* '%& #' +* B* "'= #! # H2PyrTACPh4 '
"B 0,5 / ( ’17 %) D +% +#'
"*! EE! (+B '
# *B 24 * ''"=. B +%
' '" +#*=
*B 0,5 * ''"= H2PyrTACPh4 ' ! D "B
(0,5 /). @#*% B#% "'% . 3.
V % 1200
1000
800
600
400
200
0
0
5
10
15
20
25
& '*
H2PyrTACPh4 6,0 /
H2PyrTACPh4 3,0 /
H2PyrTACPh4 1,0 /
H2PyrTACPh4 0,5 /
%. 3. %! ! 0$' "2C$
")*+" )"% AB ) %)",0"
H2PyrTACPh4 "0 0,5 $&/!& 0 0,5 24 "
"2*'
3/ 7/2008
OBO
' '%D= ("*= ' +B N-"[3,4-b](B ' & "! (%
# '#' ''" E=% '' "# "= ' '" ( EL ' "B 0,5–6,0 / B 0,5 24 * " '"= P (" B*= 54–85 %).
'
1. "
*.., " .., ?
.. <. @ P 2 278 119 (2006) // F. B+.
– 2006. – 17.
2. (
.. C%! #=%!
" '*% B% ("* "!'= * B#*= // # . – 1992. – . 3. – C. 63–132.
3. ';>
.. '% (+B% "=
("*! // !! *!
D#. – 1998. – . XLII, 5. – C. 9–16.
4. *
< .@. *! * B'=
("*! : +B // >B= "E.. – 2002. – . 6, )%. 1. – C. 4–8.
5. Dougherty T.J., Gomer C.J., Henderson B.W. et. al.
Review: photodynamic therapy // J. Natl. Cancer Inst. –
1998. – 90. – . 889–905.
6. Huang Z. A Review of Progress in Clinical Photodynamic Therapy // Technol. Cancer Res. Treat. – 2005. –
V. 4, 3 – P. 283–93.
7. Juzeniene A., Moan J. The history of PDT in Norway. Part one: Identification of basic mechanisms of general PDT // Photodiagnosis and Photodynamic Therapy. –
2007. – 4. – P. 3–11.
8. Oleinick, N.L., Morris, R.L. and Belichenko I. The
role of apoptosis in response to photodynamic therapy:
what, where, why, and how // Photochem. Photobiol. Sci.
– 2002. – 1. – . 1–21.
9. Schweitzer C., Schmidt R. Physical mechanisms of
generation and deactivation of singlet oxygen // Chem.
Rev. – 2003. – 103. – . 1685–757.
10. Xu D.Y. Research and development of photodynamic
therapy photosensitizers in China // Photodiagnosis and
Photodynamic Therapy. – 2007. – 4. – P. 13–25.
@# 22.02.2008.
CCUCU ?@?)L?CU H>